光动力疗法诱导的免疫反应机制及研究进展

中国口腔医学继续教育杂志 ›› 2022, Vol. 25 ›› Issue (4): 211-216.

光动力疗法诱导的免疫反应机制及研究进展

李林蔓, 张荷钰, 韩莹

北京大学口腔医学院·口腔医院,口腔黏膜科,国家口腔医学中心、国家口腔疾病临床医学研究中心,口腔数字化医疗技术和材料国家工程实验室

出版日期:2022-07-31 发布日期:2022-08-18
通讯作者: 韩莹,联系方式 010-82195226,电子邮箱 13683375487@163.com,通讯地址北京市海淀区中关村南大街22号,100081
基金资助:
北京大学口腔医院临床新技术新疗法项目（项目编号：PKUSSNCT-21A13）

Online:2022-07-31 Published:2022-08-18

摘要/Abstract

摘要： 光动力疗法（photodynamic therapy, PDT)已成功用于临床多种癌症的治疗及辅助治疗。此种疗法有利于减少癌症的复发,并与其他常规疗法互补,增强疗效。PDT杀伤肿瘤细胞有三种机制,本文聚焦于PDT如何引发体内的抗肿瘤免疫反应。一方面,PDT通过调节体内的中性粒细胞、补体、巨噬细胞、树突状细胞、淋巴细胞、细胞因子等,影响机体的免疫反应。另一方面,肿瘤细胞的低免疫原性使之可逃避机体免疫系统的监视,PDT诱导的免疫原性细胞死亡使肿瘤细胞质膜发生改变并易于被吞噬,并引发免疫反应的激活,从而消除残留的肿瘤细胞。随着对PDT的免疫效应机制及其诱发的免疫原性细胞死亡研究的进一步深入,临床上运用PDT治疗肿瘤将会取得更大的进步和发展,应用前景也将更广阔。

李林蔓, 张荷钰, 韩莹. 光动力疗法诱导的免疫反应机制及研究进展[J]. 中国口腔医学继续教育杂志, 2022, 25(4): 211-216.

参考文献

[1] Showalter A, Limaye A, Oyer JL, et al.Cytokines in immunogenic cell death:Applications for cancer immunotherapy[J]. Cytokine. 2017; 97:123-132.
[2] Shi X, Zhang CY, Gao J, et al.Recent advances in photodynamic therapy for cancer and infectious diseases[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019; 11(5):e1560.
[3] Rodrigues MC, Vieira LG, Horst FH, et al.Photodynamic therapy mediated by aluminium-phthalocyanine nanoemulsion eliminates primary tumors and pulmonary metastases in a murine 4T1 breast adenocarcinoma model[J]. J Photochem Photobiol B. 2020; 204:111808.
[4] Kwiatkowski S, Knap B, Przystupski D, et al.Photodynamic therapy-mechanisms, photosensitizers and combinations[J]. Biomed Pharmacother. 2018; 106:1098-1107.
[5] Alzeibak R, Mishchenko TA, Shilyagina N Y, et al.Targeting immunogenic cancer cell death by photodynamic therapy:past, present and future[J]. J Immunother Cancer. 2021; 9(1):e001926.
[6] Golla C, Bilal M, Dwucet A, et al.Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma[J]. Cancers (Basel). 2021; 13(16) :4123.
[7] Kast RE, Michael AP, Sardi I, et al.A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas:5-ALA Augmented Irradiation, the 5aai Regimen[J]. Brain Sci. 2020; 10(1):51.
[8] Nakayama T, Sano T, Oshimo Y, et al.Enhanced lipid metabolism induces the sensitivity of dormant cancer cells to 5-aminolevulinic acid-based photodynamic therapy[J]. Sci Rep. 2021; 11(1):7290.
[9] Oka T, Matsuoka KI, Utsunomiya A.Sensitive Photodynamic Detection of Adult T-cell Leukemia/Lymphoma and Specific Leukemic Cell Death Induced by Photodynamic Therapy:Current Status in Hematopoietic Malignancies[J]. Cancers (Basel). 2020; 12(2) :335.
[10] Sando Y, Matsuoka KI, Sumii Y, et al.5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy[J]. Sci Rep. 2020; 10(1):17237.
[11] Zduniak K, Gdesz-Birula K, Woźniak M, et al.The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line[J]. Molecules. 2020; 25(21) :5184.
[12] Korbelik M, Krosl G, Krosl J, et al.The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy[J]. Cancer Res. 1996; 56(24):5647-5652.
[13] Chu D, Dong X, Shi X, et al.Neutrophil-Based Drug Delivery Systems[J]. Adv Mater. 2018; 30(22):e1706245.
[14] Krosl G, Korbelik M, Dougherty GJ.Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy[J]. Br J Cancer. 1995; 71(3):549-555.
[15] Cecic I, Parkins CS, Korbelik M.Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors[J]. Photochem Photobiol. 2001; 74(5):712-720.
[16] Cecic I, Stott B, Korbelik M.Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy[J]. Int Immunopharmacol. 2006; 6(8):1259-1266.
[17] De Bruijn H S, Sluiter W, Van Der Ploeg-Van Den Heuvel A, et al. Evidence for a bystander role of neutrophils in the response to systemic 5-aminolevulinic acid-based photodynamic therapy[J]. Photodermatol Photoimmunol Photomed. 2006; 22(5):238-246.
[18] Lobo ACS, Gomes-da-Silva LC, Rodrigues-Santos P, et al. Immune Responses after Vascular Photodynamic Therapy with Redaporfin[J]. J Clin Med. 2019; 9(1) :104.
[19] Davis RW 4th, Snyder E, Miller J, et al. Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy[J]. Photochem Photobiol. 2019; 95(1):430-438.
[20] Mamidi S, Höne S, Kirschfink M.The complement system in cancer:Ambivalence between tumour destruction and promotion[J]. Immunobiology. 2017; 222(1):45-54.
[21] Cecic I, Serrano K, Gyongyossy-Issa M, et al.Characteristics of complement activation in mice bearing Lewis lung carcinomas treated by photodynamic therapy[J]. Cancer Lett. 2005; 225(2):215-223.
[22] Korbelik M, Cecic I.Complement activation cascade and its regulation:relevance for the response of solid tumors to photodynamic therapy[J]. J Photochem Photobiol B. 2008; 93(1):53-59.
[23] Korbelik M, Hamblin MR.The impact of macrophage-cancer cell interaction on the efficacy of photodynamic therapy[J]. Photochem Photobiol Sci. 2015; 14(8):1403-1409.
[24] Audiger C, Rahman MJ, Yun TJ, et al.The Importance of Dendritic Cells in Maintaining Immune Tolerance[J]. J Immunol. 2017; 198(6):2223-2231.
[25] Jalili A, Makowski M, Switaj T, et al.Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells[J]. Clin Cancer Res. 2004; 10(13):4498-4508.
[26] Wang H, Li J, Lv T, et al.Therapeutic and immune effects of 5-aminolevulinic acid photodynamic therapy on UVB-induced squamous cell carcinomas in hairless mice[J]. Exp Dermatol. 2013; 22(5):362-3363
[27] Etminan N, Peters C, Lakbir D, et al.Heat-shock protein 70-dependent dendritic cell activation by 5-aminolevulinic acid-mediated photodynamic treatment of human glioblastoma spheroids in vitro[J]. Br J Cancer. 2011; 105(7):961-969.
[28] Korbelik M, Cecic I.Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy[J]. Cancer Lett. 1999; 137(1):91-98.
[29] Kabingu E, Vaughan L, Owczarczak B, et al.CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells[J]. Br J Cancer. 2007; 96(12):1839-1848.
[30] Hendrzak-Henion JA, Knisely TL, Cincotta L, et al.Role of the immune system in mediating the antitumor effect of benzophenothiazine photodynamic therapy[J]. Photochem Photobiol. 1999; 69(5):575-581.
[31] Korbelik M, Sun J, Posakony JJ.Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors[J]. Photochem Photobiol. 2001; 73(4):403-409.
[32] Li Z, Wang C, Deng H, et al.Robust Photodynamic Therapy Using 5-ALA-Incorporated Nanocomplexes Cures Metastatic Melanoma through Priming of CD4(+)CD8(+) Double Positive T Cells[J]. Adv Sci (Weinh). 2019; 6(5):1802057.
[33] Theodoraki MN, Lorenz K, Lotfi R, et al.Influence of photodynamic therapy on peripheral immune cell populations and cytokine concentrations in head and neck cancer[J]. Photodiagnosis Photodyn Ther. 2017; 19:194-201.
[34] Prignano F, Lotti T, Spallanzani A, et al.Sequential effects of photodynamic treatment of basal cell carcinoma[J]. J Cutan Pathol. 2009; 36(4):409-416.
[35] Pucelik B, Arnaut LG, Dąbrowski JM.Lipophilicity of Bacteriochlorin-Based Photosensitizers as a Determinant for PDT Optimization through the Modulation of the Inflammatory Mediators[J]. J Clin Med. 2019;9(1):8.
[36] Reginato E, Lindenmann J, Langner C, et al.Photodynamic therapy downregulates the function of regulatory T cells in patients with esophageal squamous cell carcinoma[J]. Photochem Photobiol Sci. 2014; 13(9):1281-1289.
[37] Pellegrini C, Orlandi A, Costanza G, et al.Expression of IL-23/Th17-related cytokines in basal cell carcinoma and in the response to medical treatments[J]. PLoS One. 2017; 12(8):e0183415.
[38] Beatty GL, Gladney WL.Immune escape mechanisms as a guide for cancer immunotherapy[J]. Clin Cancer Res. 2015; 21(4):687-692.
[39] Morais JAV, Almeida LR, Rodrigues MC, et al.The induction of immunogenic cell death by photodynamic therapy in B16F10 cells in vitro is effected by the concentration of the photosensitizer[J]. Photodiagnosis Photodyn Ther. 2021; 35:102392.
[40] Obeid M, Tesniere A, Ghiringhelli F, et al.Calreticulin exposure dictates the immunogenicity of cancer cell death[J]. Nat Med. 2007; 13(1):54-61.
[41] Wang X, Ji J, Zhang H, et al.Stimulation of dendritic cells by DAMPs in ALA-PDT treated SCC tumor cells[J]. Oncotarget. 2015; 6(42):44688-44702.
[42] Ji J, Fan Z, Zhou F, et al.Improvement of DC vaccine with ALA-PDT induced immunogenic apoptotic cells for skin squamous cell carcinoma[J]. Oncotarget. 2015; 6(19):17135-17146.
[43] Yang PM, Hsieh YY, Du JL, et al.Sequential Interferon β-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner[J]. Biomolecules. 2020; 10(4):643.
[44] Gold LI, Eggleton P, Sweetwyne MT, et al.Calreticulin: non-endoplasmic reticulum functions in physiology and disease[J]. Faseb j. 2010; 24(3):665-683.
[45] Seelige R, Searles S, Bui JD.Mechanisms regulating immune surveillance of cellular stress in cancer[J]. Cell Mol Life Sci. 2018; 75(2):225-240.
[46] Li W, Yang J, Luo L, et al.Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death[J]. Nat Commun. 2019; 10(1):3349.
[47] Kuppner M C, Gastpar R, Gelwer S, et al.The role of heat shock protein (hsp70) in dendritic cell maturation:hsp70 induces the maturation of immature dendritic cells but reduces DC differentiation from monocyte precursors[J]. Eur J Immunol. 2001; 31(5):1602-1609.
[48] Castano AP, Mroz P, Hamblin MR.Photodynamic therapy and anti-tumour immunity[J]. Nat Rev Cancer. 2006; 6(7):535-545.
[49] Yang H, Wang H, Chavan S S, et al. High Mobility Group Box Protein 1 (HMGB1):The Prototypical Endogenous Danger Molecule[J]. Mol Med.2015; 21 Suppl 1(Suppl 1):S6-s12.
[50] Inoue H, Tani K.Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments[J]. Cell Death Differ. 2014; 21(1):39-49.
[51] Xie Y, Yu N, Chen Y, et al.HMGB1 regulates P-glycoprotein expression in status epilepticus rat brains via the RAGE/NF-κB signaling pathway[J]. Mol Med Rep. 2017; 16(2):1691-1700.
[52] De Groof T W M, Mashayekhi V, Fan T S, et al. Nanobody-Targeted Photodynamic Therapy Selectively Kills Viral GPCR-Expressing Glioblastoma Cells[J]. Mol Pharm. 2019; 16(7):3145-3156.
[53] Liu J, Zhao X, Nie W, et al.Tumor cell-activated “Sustainable ROS Generator” with homogeneous intratumoral distribution property for improved anti-tumor therapy[J]. Theranostics. 2021; 11(1):379-396.
[54] SHOFOLAWE-BAKARE O T, STOKES L D, HOSSAIN M, et al. Immunostimulatory biomaterials to boost tumor immunogenicity[J]. Biomater Sci, 2020, 8(20): 5516-37.
[55] BONAVENTURA P, SHEKARIAN T, ALCAZER V, et al.Cold Tumors: A Therapeutic Challenge for Immunotherapy[J]. Front Immunol, 2019, 10: 168.
[56] YIN Z, YU M, MA T, et al.Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1[J]. J Immunother Cancer, 2021, 9(1).